Abstract: The invention relates to cationic block copolymers of formula A(—X—B)n or C(—Y—D)m, wherein A represents a hydrophilic polymer, B represents polyethyleneimine (PEI), X represents a bridge, n represents 1-200, C represents PEI, D represents the residue of a polyethylene glycol, Y represents a bridge and m represents 1-200. The invention also relates to methods for producing the inventive cationic block polymers and to their use e.g. as a tenside and for complexing nucleic acids.

Abstract: Microparticles comprising at least one active agent embedded within a biocompatible, biodegradable polymeric matrix, wherein said microparticles are prepared with an ionic liquid.

Abstract: The invention provides a polytartrate composition for pulsatile release of a pharmaceutically active material that is in the form of a compressed tablet, and a process for preparing such a composition.

Abstract: The invention relates to the complexation of RNA with optionally modified polyethylenimines for extracellular and intracellularin vitro and in vivo stabiliztion thereof and for cellular introduction of the complexed RNA in cells. The invention also relates to chemically modified or non-modified, natural or synthetic ribozymes complexes and polyethylenimine (PEI) having any chain length, molar mass and degree of branching, which is chemically modified or non-chemically modified. The invention further relates to the production of complexes and to the use thereof in the protection of RNA against enzymatic and non-enzymatic degradation and their reception in vitro or in vivo in cells. The biological activity of the ribozymes remains intact.

Abstract: The present invention relates to microparticles for the delayed release of a physiologically active ingredient, said particles containing at least one active ingredient and a polymer matrix. The microparticles of the present invention possess particularly advantageous release characteristics. The present invention also relates to a method for manufacturing microparticles of the aforementioned kind.

Abstract: The invention concerns liposomal preparations comprising as the active agent a compound of formula I in free base form or in acid addition salt form. It also concerns a method of preparation of such liposomal preparations by encapsulating a compound of formula I with an appropriate liposome forming material, a corresponding pharmaceutical compositions, and methods of treatment of systemic, topical and pulmonal fungal infections.

Abstract: The invention is directed to self-assembling, polymer-based delivery systems for proteins. The delivery systems comprises an active agent and a polyol ester of the invention, having a linear polyol containing six or more hydroxyl groups as a central backbone and biodegradable hydroxy carboxylic ester groups attached to the central backbone.

Abstract: The invention relates to low molecular weight polyethylenimines, to vectors for inserting nucleic acids into cells which contain low molecular weight polyethylenimines, and to the preparation and use of the low molecular weight polyethylenimine and the vector.

Abstract: Target cell-specific, non-viral vectors for inserting genes into cells, pharmaceuticals composition comprising such vectors, and methods of their use. Target cell-specific, non-viral vectors for inserting at least one gene into cells of an organism, comprising a complex comprising the following components: a) a non-viral carrier for the gene to be inserted, b) a ligand which can bind specifically to the desired target cell, c) a fusion protein for the penetration of the vector into the cytoplasm of the target cell, and d) the gene to be introduced are disclosed. Vectors of this nature are used, for example, in gene therapy.

Abstract: The invention concerns parenteral pharmaceutical forms of administration containing polypeptide in the form of microparticles and a process for the production thereof. The microparticles according to the invention contain as a biodegradable polymer an ABA triblock copolymer the A block of which is a copolymer of lactic and glycolic acid and the B block of which represents a polyethylene glycol chain, together with additives that are selected from the group comprising serum proteins, polyamino acids, cyclodextrins, cyclodextrin derivatives, saccharides, amino sugars, amino acids, detergents or carboxylic acids as well as mixtures of these additives. The microparticles according to the invention continuously release the polypeptide over a relatively long time period even when the amounts of polypeptide they include are small or susceptible to aggregation.

Abstract: The invention is directed to self-assembling, polymer-based delivery systems for proteins. The delivery systems comprises an active agent and a polyol ester of the invention, having a linear polyol containing six or more hydroxyl groups as a central backbone and biodegradable hydroxy carboxylic ester groups attached to the central backbone.

Abstract: The invention concerns a transdermal application system for antithrombotic therapy and for the prophylaxis against cancer, respectively, containing as active substance acetylsalicylic acid and/or pharmaceutically acceptable salts thereof.

Abstract: The invention relates to new polyesters of a polyol containing substituents with electrolyte properties with polymeric hydroxycarboxylic esters, their method of preparation and their use. The polyesters are particularly suitable for use in the preparation of sustained-release drugs.

Abstract: This invention provides a polyester of a polyol, said polyol containing at least 3 hydroxyl groups and having a molecular weight of up to 20,000 at least 1 hydroxyl group in said polyol being in the form of an ester, with a poly- or co-poly-lactic acid residue, each having a molecular weight of at least 5,000. These are useful for parenteral depot formulations.

Abstract: This invention provides a polyester of a polyol, said polyol containing at least 3 hydroxyl groups and having a molecular weight of up to 20,000 at least 1 hydroxyl group in said polyol being in the form of an ester, with a poly- or co-poly-lactic acid residue, each having a molecular weight of at least from 5,000. These are useful for parenteral depot formulations.

Abstract: Target cell-specific, non-viral vectors for inserting genes into cells, pharmaceuticals composition comprising such vectors, and methods of their use. Target cell-specific, non-viral vectors for inserting at least one gene into cells of an organism, comprising a complex comprising the following components:a) a non-viral carrier for the gene to be inserted,b) a ligand which can bind specifically to the desired target cell,c) a fusion protein for the penetration of the vector into the cytoplasm of the target cell, andd) the gene to be introducedare disclosed. Vectors of this nature are used, for example, in gene therapy.

Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.

Abstract: A transdermal therapeutic system for antithrombotic therapy is disclosed. The system comprises a hydrophobic polymer matrix, acetic anhydride, and acetylsalicylic acid as the only active ingredient.

Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.

Abstract: The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide)glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.